Lattice Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Lattice Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,600	Closed	-$1.15M	–	40
2023 Q2	$1.15M	Hold	1,600	–	–	0.15%	15
2023 Q1	$1.31M	Hold	1,600	–	–	0.19%	16
2022 Q4	$1.15M	Hold	1,600	–	–	0.19%	16
2022 Q3	$1.1M	Hold	1,600	–	–	1.76%	16
2022 Q2	$963K	Hold	1,600	–	–	0.12%	18
2022 Q1	$1.17M	Hold	1,600	–	–	1.67%	15
2021 Q4	$1.01M	Buy	+1,600	New	+$984K	0.07%	30

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lattice Capital Management's REGN Position: Q3 2023 in Review

Lattice Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2023, closing a stake of 1,600 shares — an estimated $1.15M sold.

Lattice Capital Management first reported a position in REGN in Q4 2021 and held it in 7 quarters. The position peaked at $1.31M in Q1 2023. 1,178 funds tracked by Wall St. Rank hold REGN as of Q3 2023.

Lattice Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Lattice Capital Management sold 1,600 Regeneron Pharmaceuticals shares in Q3 2023, an estimated $1.15M.
Lattice Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 7 quarters.
Lattice Capital Management's Regeneron Pharmaceuticals position peaked at $1.31M in Q1 2023.
1,178 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2023.

Based on Lattice Capital Management's 13F filing for Q3 2023, filed 1 Nov 2023.